Gastroenterology

Upadacitinib shows promise as maintenance therapy for active ulcerative colitis

Upadacitinib, an oral JAK inhibitor, has shown significant efficacy as a maintenance therapy for patients with moderately to severely active ulcerative colitis, according to a study. The study demonstrated that both maintenance doses of upadacitinib led to a higher proportion of patients achieving clinical remission compared to placebo. In this...